These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36715822)

  • 1. Wnt/β-catenin pathway inhibitors, bone metabolism and vascular health in kidney transplant patients.
    Wang YP; Sidibé A; Fortier C; Desjardins MP; Ung RV; Kremer R; Agharazii M; Mac-Way F
    J Nephrol; 2023 May; 36(4):969-978. PubMed ID: 36715822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels.
    Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM
    Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects.
    Stavrinou E; Sarafidis PA; Koumaras C; Loutradis C; Giamalis P; Tziomalos K; Karagiannis A; Papagianni A
    Kidney Blood Press Res; 2019; 44(4):679-689. PubMed ID: 31382263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.
    Desbiens LC; Sidibé A; Ung RV; Fortier C; Munger M; Wang YP; Bisson SK; Marquis K; Agharazii M; Mac-Way F
    Osteoporos Int; 2018 Oct; 29(10):2345-2353. PubMed ID: 29959497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study.
    Hsu BG; Liou HH; Lee CJ; Chen YC; Ho GJ; Lee MC
    Medicine (Baltimore); 2016 Apr; 95(15):e3300. PubMed ID: 27082570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
    Carrillo-López N; Panizo S; Alonso-Montes C; Román-García P; Rodríguez I; Martínez-Salgado C; Dusso AS; Naves M; Cannata-Andía JB
    Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
    BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients.
    Chang YC; Hsu BG; Liou HH; Lee CJ; Wang JH
    BMC Cardiovasc Disord; 2018 Nov; 18(1):214. PubMed ID: 30482161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between sclerostin and Dickkopf-1 with aortic arterial stiffness in patients with type 2 diabetes: A prospective, cross-sectional study.
    Yang HY; Wu DA; Chen MC; Hsu BG
    Diab Vasc Dis Res; 2019 May; 16(3):281-288. PubMed ID: 30547685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uremic toxicity and sclerostin in chronic kidney disease patients.
    Desjardins L; Liabeuf S; Oliveira RB; Louvet L; Kamel S; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
    Nephrol Ther; 2014 Nov; 10(6):463-70. PubMed ID: 25070604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial Stiffness and the Canonical WNT/β-catenin Pathway.
    Vallée A
    Curr Hypertens Rep; 2022 Nov; 24(11):499-507. PubMed ID: 35727523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin and DKK1: new players in renal bone and vascular disease.
    Evenepoel P; D'Haese P; Brandenburg V
    Kidney Int; 2015 Aug; 88(2):235-40. PubMed ID: 26083653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin is a possible candidate marker of arterial stiffness: Results from a cohort study in Catania.
    Gaudio A; Fiore V; Rapisarda R; Sidoti MH; Xourafa A; Catalano A; Tringali G; Zanoli L; Signorelli SS; Fiore CE
    Mol Med Rep; 2017 May; 15(5):3420-3424. PubMed ID: 28339088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.
    de Oliveira RB; Graciolli FG; dos Reis LM; Cancela AL; Cuppari L; Canziani ME; Carvalho AB; Jorgetti V; Moysés RM
    Nephrol Dial Transplant; 2013 Oct; 28(10):2510-7. PubMed ID: 23975746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease.
    Muñoz-Castañeda JR; Rodelo-Haad C; Pendon-Ruiz de Mier MV; Martin-Malo A; Santamaria R; Rodriguez M
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32188018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway.
    Schiavi SC; Moysés RM
    Kidney Int; 2016 Jul; 90(1):17-20. PubMed ID: 27312441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.